LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
| Autor: | Chan, J., Geyer, S., Ou, F-S., Knopp, M., Behr, S., Zemla, T., Acoba, J., Shergill, A., Wolin, E.M., Halfdanarson, T.R., Trikalinos, N., Konda, B., Vijayvergia, N., Dasari, N.A., Strosberg, J., Kohn, E.C., Kulke, M.H., O'Reilly, E.M., Meyerhardt, J.A. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S1292-S1292 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|